Vanda Pharmaceuticals (VNDA) Retained Earnings (2016 - 2025)
Historic Retained Earnings for Vanda Pharmaceuticals (VNDA) over the last 17 years, with Q3 2025 value amounting to -$253.6 million.
- Vanda Pharmaceuticals' Retained Earnings fell 4971.01% to -$253.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$253.6 million, marking a year-over-year decrease of 4971.01%. This contributed to the annual value of -$174.3 million for FY2024, which is 1216.28% down from last year.
- As of Q3 2025, Vanda Pharmaceuticals' Retained Earnings stood at -$253.6 million, which was down 4971.01% from -$231.0 million recorded in Q2 2025.
- Vanda Pharmaceuticals' 5-year Retained Earnings high stood at -$153.0 million for Q3 2023, and its period low was -$253.6 million during Q3 2025.
- Its 5-year average for Retained Earnings is -$175.6 million, with a median of -$168.0 million in 2022.
- Per our database at Business Quant, Vanda Pharmaceuticals' Retained Earnings skyrocketed by 1680.05% in 2021 and then tumbled by 4971.01% in 2025.
- Quarter analysis of 5 years shows Vanda Pharmaceuticals' Retained Earnings stood at -$164.2 million in 2021, then increased by 3.82% to -$157.9 million in 2022, then increased by 1.59% to -$155.4 million in 2023, then dropped by 12.16% to -$174.3 million in 2024, then crashed by 45.49% to -$253.6 million in 2025.
- Its Retained Earnings stands at -$253.6 million for Q3 2025, versus -$231.0 million for Q2 2025 and -$203.8 million for Q1 2025.